Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Chief Science Officer, Peter Surman, shares insight on why pharmaceutical companies should consider softgels for their next ...

Aims to establish a qualification strategy for operating PAS-X MES in the AWS Cloud in compliance with regulatory ...

The U.S. Food and Drug Administration (FDA) has accepted Sobi’s supplemental Biologics License Application (sBLA) for ...

Eli Lilly and Company has announced plans to bolster its domestic medicine production across therapeutic areas by building ...

Direct Data API, a new class of API, is now included for no additional license fee as part of Veeva Vault Platform.

International Process Plants (IPP), a leader in repurposing industrial manufacturing sites, has leased its fermentation-based ...

Sygnature Discovery has appointed Kieron Hall as its new Chief Commercial Officer and Board member. Kieron will play a key ...

Transitional outsourcing models, combined with a broken site feasibility process, could open opportunities for CROs to ...